CRMD vs. VTYX, NATR, RANI, AQST, ME, XOMA, NLTX, VNDA, INZY, and CTNM Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Ventyx Biosciences (VTYX), Nature's Sunshine Products (NATR), Rani Therapeutics (RANI), Aquestive Therapeutics (AQST), 23andMe (ME), XOMA (XOMA), Neoleukin Therapeutics (NLTX), Vanda Pharmaceuticals (VNDA), Inozyme Pharma (INZY), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical preparations" industry.
Ventyx Biosciences (NASDAQ:VTYX ) and CorMedix (NASDAQ:CRMD ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.
Ventyx Biosciences received 12 more outperform votes than CorMedix when rated by MarketBeat users. However, 71.43% of users gave CorMedix an outperform vote while only 49.09% of users gave Ventyx Biosciences an outperform vote.
97.9% of Ventyx Biosciences shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 24.4% of Ventyx Biosciences shares are owned by insiders. Comparatively, 3.6% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Ventyx Biosciences presently has a consensus price target of $21.75, suggesting a potential upside of 359.83%. CorMedix has a consensus price target of $13.00, suggesting a potential upside of 153.91%. Given CorMedix's higher possible upside, research analysts plainly believe Ventyx Biosciences is more favorable than CorMedix.
CorMedix's return on equity of -65.94% beat Ventyx Biosciences' return on equity.
In the previous week, Ventyx Biosciences and Ventyx Biosciences both had 6 articles in the media. Ventyx Biosciences' average media sentiment score of 0.62 beat CorMedix's score of 0.28 indicating that CorMedix is being referred to more favorably in the news media.
Ventyx Biosciences has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500.
CorMedix has higher revenue and earnings than Ventyx Biosciences. CorMedix is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary Ventyx Biosciences beats CorMedix on 8 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
CorMedix Competitors List
Related Companies and Tools
